Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-TARGET precision medicine trial in relapsed or refractory T-cell acute lymphoblastic leukemia
NL-OMON61185Phase 2Not yet recruiting
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib, venetoclax, everolimus, crisantaspase recombinant, azacitidine in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Centre Hospitalier de Versailles. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NL-OMON61185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61185.